Perseus PCI is excited to announce that they will be heavily subsidizing the treatment of 20 patients with stage 3 or 4 melanoma. The subsidy is being offered in order to make it possible for these patients to complete treatment as soon as possible, making the data available for future FDA submissions. Perseus PCI has licensed the cutting edge immunotherapy cancer treatment developed by Orbis Heath Solutions, LLC that works by using the entire molecular content of your own cancer cells to create a personalized vaccine. The vaccine has shown promising results in US trials since 2002 and recent treatments in the Cayman Islands.. There is no good systemic therapy for stage 3 and 4 melanoma. The Perseus Melanoma Registry Program was founded for the purpose of developing just that therapy as quickly as possible.
Immunotherapy was named the “breakthrough of the year” by Science Magazine in 2013, and our hope is that the launch of our registry program in 2014 will help advance this breakthrough even further. In addition to the heavily subsidized nature of the registry program, patients have the comfort of knowing that unlike a formal trial, there will be no placebo controls in place during this process. Every patient knows they will be receiving the real working vaccine that has already helped many people.
We hope that you will take the time to learn more about this effective melanoma therapy, read and hear our patient stories, and consider applying for our registry program. Almost all of us have been affected by this disease personally or through family and friends. If you know someone, please share this website with them.
Clinical trials of a cancer vaccine for patients with a specific stage of melanoma have begun at Perseus, a Cayman company that specializes in personalized cancer immunotherapeutics (PCI) that treat solid tumors. Read More
New Registry Opens for Patients Seeking Effective, Non-Toxic Treatment for Advanced Melanoma: Perseus PCI’s Promising VACCINE for Cancer Takes Next Step Toward FDA Trials Twenty cancer patients will be approved for $40,000 subsidy. With years of compelling safety and efficacy data documented on stage III and IV melanoma patients, Perseus PCI, Inc. will take the next important step toward making their cancer immunotherapy vaccine more acceptable and available worldwide. Read More
Health and hope shine brightly this holiday season for patient diagnosed with ‘incurable’ cancer. Perseus PCI vaccine, a breakthrough Alternative Cancer Treatment Read More
Personalized immunotherapy vaccine developed by Perseus PCI offers breakthrough, non-toxic treatment for cancer patients that uses the body's own cells to attack tumors and turn off the engine of cancer inside the body. Read More